In connection with its Q3 business review, Bioretec shed light on its situation and the commercial challenges of the RemeOs product family. The company is seeking new commercial momentum through recruitment and revisions to its distribution model. Further, the company is preparing a strategy update, which is to be launched by the end of the year. Bioretec's CEO Sarah Hubar-Fisher in an interview with analyst Antti Siltanen.
Topics:
00:00 Introduction
00:12 H1 figures revisions
01:20 Summary of the third quarter
02:34 Gross profit
03:51 Status of the RemeOs launch in Europe
04:48 Reasons for the distribution model revision
07:23 Increased headcount
09:05 Change negotiations
10:30 Targets and strategy update
11:39 Timeline for clinical trial
12:32 Screw model approvals and indication expansions in the US
13:23 Cash runway
14:08 Turning the cash flow positive
14:45 Outlook for the rest of the year and 2026